Summary
OPGN Chart
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OpGen (NASDAQ: OPGN ) just reported results for the second quarter of 2024. OpGen reported earnings per share of -$1.18.
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen (NASDAQ: OPGN ) just reported results for the fourth quarter of 2023. OpGen reported earnings per share of -$17.67.
OpGen Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YC Yi Chen HC Wainwright & Co. | - | - | - | - | - |
OpGen Inc. (OPGN) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
OpGen Inc. Profile
| Professional Services Industry | Industrials Sector | Christian-Laurent Benoit Bonte CEO | OTC PINK Exchange | 68373L307 CUSIP |
| US Country | 4 Employees | 29 Aug 2019 Last Dividend | 20 May 2024 Last Split | 5 May 2015 IPO Date |
Overview
OpGen, Inc. is a pioneering precision medicine company that focuses on developing and commercializing molecular microbiology solutions both within the United States and around the globe. The organization specifically targets the fast-evolving sector of antimicrobial resistance (AMR), offering advanced diagnostic tools, analytics, and information to healthcare providers. This enables more effective management and treatment of life-threatening infections, particularly those caused by multidrug-resistant organisms. Founded in 2001 and based in Rockville, Maryland, OpGen has established collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, enhancing its efforts in combating the spread and impact of antimicrobial resistance through innovative research programs aimed at healthcare institutions.
Products and Services
- Acuitas AMR Gene Panel
An in vitro diagnostic test designed to detect and identify various bacterial nucleic acids along with genetic markers of antimicrobial resistance (AMR) from bacterial colonies, regardless of the specimen origin. This powerful diagnostic tool plays a crucial role in determining the presence of AMR genes, enabling healthcare providers to choose the most effective treatments.
- Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits
These test kits utilize advanced polymerase chain reaction (PCR) technology to accurately detect SARS-CoV-2, the virus responsible for COVID-19. Having received CE-IVD marking, these kits meet stringent quality and safety standards, providing reliable results essential for controlling the spread of COVID-19.
- ARES Technology Platform
An integrated platform that utilizes next-generation sequencing technology and artificial intelligence to maintain a reference database on antimicrobial resistance. The ARES platform aids in antibiotic response prediction by providing detailed insights into antimicrobial resistance mechanisms, supporting the development of effective treatment strategies.
- Unyvero Platform
An automated sample-to-answer molecular diagnostics platform that simplifies the detection of pathogens and antibiotic resistance markers. By integrating automated sample preparation, analysis, and identification processes, the Unyvero Platform significantly reduces the time and effort required to diagnose severe infectious diseases, thereby improving patient outcomes and healthcare efficiency.
